Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGEN-123
- Development stage
- Preclinical
- Lead developer
- NEUVOGEN
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
NGEN-123 is an allogeneic, off-the-shelf whole tumor cell vaccine being developed by NEUVOGEN for the treatment of pancreatic cancer. The vaccine is based on a proprietary platform that utilizes genetically modified tumor cell lines engineered to present a broad spectrum of tumor antigens to the immune system. Unlike vaccines targeting a single molecular marker, NGEN-123 is designed to address tumor heterogeneity by priming a multi-antigenic immune response. The platform incorporates proprietary activation technology to enhance the immunogenicity of the cell lines, aiming to stimulate a robust anti-tumor response in patients with pancreatic cancer.
- Other names
- NEUVOGEN pancreatic cancer vaccine
Beyond the preview
Go deeper on NGEN-123.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGEN-123.